Overview
- The Neurology paper, published August 12, analyzed records from the National Alzheimer’s Coordinating Center and ADNI covering 21,462 women and found estrogen-only users had about 35% lower odds of meeting autopsy criteria for Alzheimer’s disease.
- The study also found lower amyloid levels in blood and cerebrospinal fluid and lower odds of clinical dementia diagnosis and memory or functional decline among estrogen-only users.
- The analysis is retrospective and observational, relied on self-reported estrogen use, lacked consistent data on hysterectomy timing and topical formulations, and the cohorts were majority white, so the findings cannot prove cause.
- Results apply mainly to estrogen-only regimens typically prescribed to women without a uterus and to participants who on average began therapy near age 70, which differs from current menopausal practice.
- Authors and outside experts urge targeted prospective research, especially randomized trials that test when to start therapy, which formulations help, how APOE status affects benefit, and longer-term safety before clinical recommendations change.